Catalyst
Slingshot members are tracking this event:
Paratel (PRTK) Completes Enrollment in Phase 3 Trial Evaluating Omadacycline in Treatment of Community Acquired Bacterial Pneumonia (CABP)
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| PRTK |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jan 18, 2017
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Enrollment, Phase 3, Omadacycline, Community Acquired Bacterial Pneumonia, Cabp
